JPMorgan Chase & Co. started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a report released on Monday, MarketBeat reports. The brokerage issued an overweight rating and a $25.00 target price on the biopharmaceutical company’s stock.
A number of other research analysts also recently commented on the stock. BidaskClub raised shares of Intra-Cellular Therapies from a strong sell rating to a sell rating in a research report on Tuesday, February 13th. Royal Bank of Canada began coverage on shares of Intra-Cellular Therapies in a research report on Thursday, February 8th. They set an outperform rating and a $33.00 price objective on the stock. Zacks Investment Research downgraded shares of Intra-Cellular Therapies from a buy rating to a hold rating in a research report on Tuesday, January 23rd. Finally, ValuEngine downgraded shares of Intra-Cellular Therapies from a sell rating to a strong sell rating in a research report on Sunday, December 31st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. Intra-Cellular Therapies currently has a consensus rating of Buy and a consensus price target of $26.55.
Intra-Cellular Therapies (NASDAQ ITCI) opened at $20.36 on Monday. Intra-Cellular Therapies has a 1 year low of $7.85 and a 1 year high of $22.67.
Several hedge funds and other institutional investors have recently bought and sold shares of ITCI. Russell Investments Group Ltd. bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter worth $101,000. Quantbot Technologies LP boosted its holdings in shares of Intra-Cellular Therapies by 233.1% during the 3rd quarter. Quantbot Technologies LP now owns 8,614 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 6,028 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Intra-Cellular Therapies by 45.9% during the 3rd quarter. SG Americas Securities LLC now owns 12,060 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 3,794 shares during the period. Voya Investment Management LLC boosted its holdings in shares of Intra-Cellular Therapies by 16.0% during the 2nd quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 2,338 shares during the period. Finally, Teacher Retirement System of Texas bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth $212,000. 76.93% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Intra-Cellular Therapies (ITCI) Coverage Initiated by Analysts at JPMorgan Chase & Co.” was first posted by Ticker Report and is owned by of Ticker Report. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3225302/intra-cellular-therapies-itci-coverage-initiated-by-analysts-at-jpmorgan-chase-co.html.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.